Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Glucagon-Like Peptide-1 Receptor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT07610174
What this trial is testing

Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

Who this might be right for
Heart FailureHeart Valve Prosthesis
Kafrelsheikh University 160
Post-approval studies (Phase 4)WithdrawnNCT02920190
What this trial is testing

Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat

Who this might be right for
Monoclonal GammopathiesOverweightObesity
University of Miami
Not applicableStudy completedNCT00937079
What this trial is testing

Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

Who this might be right for
HyperinsulinismHypoglycemiaInsulinoma
University Hospital, Basel, Switzerland 30
Not applicableStudy completedNCT04184947
What this trial is testing

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Who this might be right for
Type 2 Diabetes
University of Padova 10,000
Post-approval studies (Phase 4)Not Yet RecruitingNCT07756359
What this trial is testing

Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

Who this might be right for
Pouch, IlealPouches, IleoanalBowel Diseases, Inflammatory
University of North Carolina, Chapel Hill 20
Not applicableNot Yet RecruitingNCT07621640
What this trial is testing

Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)

Who this might be right for
ObesityMetabolic SyndromeBrown Adipose Tissue
Hallym University 80
Not applicableLooking for participantsNCT07065383
What this trial is testing

Rebalancing the Fat Content of the Heart and Muscles

Who this might be right for
Diabetes Mellitus Type 2
University of Aberdeen 60
Early research (Phase 1)Not Yet RecruitingNCT06601517
What this trial is testing

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

Who this might be right for
Healthy Adult SubjectOverweight Subject
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 30
Not applicableLooking for participantsNCT07835360
What this trial is testing

Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes

Who this might be right for
Obesity (Disorder)Type 2 Diabetes Mellitus
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07614412
What this trial is testing

SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

Who this might be right for
Type 1 Diabetes Mellitus
Ministry of Health, Saudi Arabia 240
Large-scale testing (Phase 3)Study completedNCT04459338
What this trial is testing

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

Who this might be right for
Healthy
Adrian Vella 11
Post-approval studies (Phase 4)Not Yet RecruitingNCT07547878
What this trial is testing

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Who this might be right for
Chronic Kidney DiseaseType 2 Diabetes
Baylor Research Institute 64
Very early researchLooking for participantsNCT07012642
What this trial is testing

Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

Who this might be right for
Lymphedema
Advanced Reconstructive Surgery Alliance 110
Large-scale testing (Phase 3)Looking for participantsNCT07218354
What this trial is testing

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

Who this might be right for
Alcohol Use Disorder
VA Office of Research and Development 622
Large-scale testing (Phase 3)Study completedNCT06584916
What this trial is testing

Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

Who this might be right for
ObesityOverweight
Eli Lilly and Company 376
Large-scale testing (Phase 3)Study completedNCT02229227
What this trial is testing

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Who this might be right for
Diabetes Mellitus, Type 2
GlaxoSmithKline 814
Not applicableActive Not RecruitingNCT06234111
What this trial is testing

Semaglutide and Physical Activity for Obesity and Multimorbidity

Who this might be right for
Obesity MorbidMultimorbidityObesity
Hvidovre University Hospital 35
Early research (Phase 1)Study completedNCT01304823
What this trial is testing

Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY

Who this might be right for
Taste Disorder, Primary, Sweet
University Hospital, Basel, Switzerland 10
Post-approval studies (Phase 4)Study completedNCT02291874
What this trial is testing

Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)

Who this might be right for
Type 2 Diabetes Mellitus
Astellas Pharma Inc 100
Large-scale testing (Phase 3)UnknownNCT02718950
What this trial is testing

Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

Who this might be right for
ObesityType 2 Diabetes Mellitus
University of Campinas, Brazil 20
Next Page